International Symposium on Juvenile Myelomonocytic Leukemia

我们正在请求支持为研究青少年的研究人员举行的年度科学会议提供支持 粒单核细胞白血病(JMML)。此外，几名治疗医生和家庭 患有这种疾病的儿童将被邀请参加。JMML是一种激进的 影响婴幼儿的白血病。它很快就会致命，而且对 化疗一般都是短暂的。目前，唯一已知的治疗方法是通过 造血干细胞移植，这可能会对这些人产生毁灭性的发育影响 年幼的孩子。在过去的几年里，已经取得了几项重要的科学突破 几年来坚定地认为RAS/MAPK通路的过度激活是 在这种疾病中的事件。鉴于对致癌RAS在肿瘤形成中作用的积极研究 以及对这种致命疾病改进治疗的需要，这次会议是在 哪些基础科学研究人员、临床科学家、监管科学家和家庭成员 受影响的人可以进行互动和协作。JMML基金会年度研讨会 因此有四个主要目标：1.分享JMML科学和临床的最新发展 通过促进国内和国际领先领导人的高水平演讲进行研究 2.提供场地，策划和推行创新的临床试验 这种疾病的患者；3.促进JMML调查人员和 患者权益倡导者；以及4.提供一个论坛，让JMML的初级调查人员可以在其中介绍 他们的工作以及彼此之间的互动，以及与外地高级调查人员的互动。支持是 寻求连续五年，会议与美国联合举行 血液学学会。通过这种方式，我们将利用并继续取得成功。 在以前的会议中确定的国际合作。2007年会议将于12月举行 6-7在佐治亚州亚特兰大。这次会议的主讲人是Mignon Loh，医学博士，他是 JMML基金会董事会。她和她的同事克里斯蒂安·克拉茨博士和 Kevin Shannon将在JMML基金会的组织支持下计划这次会议。一个 预计将有50-60人参加。将特别注意包括 初级研究员、博士后研究员以及来自代表性不足的临床医生和科学家 社区。这项拨款申请要求支持一个年度科学会议，会议的主题是 连续五年幼年粒单核细胞白血病的生物学研究 这些会议将与美国协会联合举行 血液学会议。这次研讨会将集中讨论最近在 JMML的发病机制，邀请了科学家和临床医生 在RAS信号通路、临床前治疗和 进行人体临床试验。总体目标是提供一个机会 供研究人员、医生和内科科学家共享数据和 为患有这种攻击性疾病的儿童实施创新疗法 骨髓增生性疾病。

We are requesting support for an annual scientific meeting for investigators studying juvenile myelomonocytic leukemia (JMML). In addition, several treating physicians and families of children afflicted with this disease will be invited to attend. JMML is an aggressive form of leukemia that affects infants and young children. It is rapidly fatal, and responses to chemotherapy are generally shortlived. Currently, the only known cures are achieved through hematopoietic stem cell transplants, which can have devastating developmental effects on these young children. Several important scientific breakthroughs have been made over the past several years that firmly implicate hyperactivation of the Ras/MAPK pathway as the initiating event in this disease. Given the active investigation of the role of oncogenic Ras in neoplasia and the need for improved therapies for this fatal disease, this meeting serves a critical venue in which basic science investigators, clinical scientists, regulatory scientists, and family members of those affected can interact and collaborate. The annual symposium of the JMML foundation thus has four major goals: 1. to share the latest developments in JMML scientific and clinical research by fostering high level presentations from leading national and international leaders in the field; 2. to provide a venue for planning and implementing innovative clinical trials for patients with this disease; 3. to facilitate communication between JMML investigators and patient advocates; and 4. to provide a forum in which junior investigators in JMML can present their work and interact with each other and with senior investigators in the field. Support is sought for five consecutive years, with meetings being held in conjunction with the American Society of Hematology. In this manner, we will capitalize on and continue successful international collaborations set during prior meetings. The 2007 meeting will be held December 6-7 in Atlanta, Georgia. The PI of this meeting is Mignon Loh, MD, who is a member of the board of directors of The JMML Foundation. She and her colleagues, Drs. Christian Kratz and Kevin Shannon will plan the meeting with organizational support from The JMML Foundation. A total of 50-60 participants are anticipated to attend. Special attention will be made to include junior investigators, post-doctoral fellows, and clinicians and scientists from underrepresented communities. This grant application requests support for an annual scientific meeting focused on the biology of Juvenile Myelomonocytic Leukemia for five consecutive years. The meetings will be held in conjunction with the American Society of Hematology meetings. This symposium will focus on recent advances in the pathogenesis of JMML, with invited scientists and clinicians who have demonstrated expertise in Ras pathway signaling, pre-clinical therapeutics, and the conduct of human clinical trials. The overall goal is to provide an opportunity for researchers, physicians, and physician-scientists to share data and implement innovative therapies for children afflicted with this aggressive myeloproliferative disorder.